SCHEMBL16676911

SCHEMBL16676911

COc1cc(OC)c(Cl)c(-c2ccc3nc(N)ncc3c2)c1Cl

nearest known ligand 0.66

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 15/20 0.66
FGFR1 P11362 6/20 0.53
FGFR2 P21802 4/20 0.53
FGFR3 P22607 4/20 0.53
RPS6KB2 Q9UBS0 1/20 0.52
LCK P06239 4/20 0.49
KIT P10721 3/20 0.49
SRC P12931 3/20 0.49
KDR P35968 1/20 0.49
JAK3 P52333 1/20 0.49
MAPK14 Q16539 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21153337 0.92 FGFR4 (0.57) FGFR4FGFR1FGFR2FGFR3RPS6KB2
SCHEMBL22781190 0.91 FGFR4 (0.56) FGFR4FGFR1FGFR2FGFR3RPS6KB2
SCHEMBL21153647 0.89 FGFR4 (0.54) FGFR4FGFR1FGFR2FGFR3RPS6KB2
SCHEMBL19943434 0.88 LCK (0.53) FGFR4LCKKITSRCKDR
SCHEMBL21153914 0.87 FGFR4 (0.51) FGFR4FGFR1FGFR2FGFR3RPS6KB2
SCHEMBL29385382 0.86 FGFR4 (0.69) FGFR4FGFR1FGFR2FGFR3RPS6KB2
SCHEMBL15412791 0.86 FGFR4 (0.69) FGFR4FGFR1FGFR2FGFR3RPS6KB2
SCHEMBL16683513 0.85 FGFR4 (0.67) FGFR4FGFR1FGFR2FGFR3RPS6KB2
SCHEMBL5489026 0.83 LCK (0.55) FGFR4LCKKITSRCKDR
SCHEMBL24335995 0.82 FGFR1 (0.56) FGFR4FGFR1FGFR2FGFR3RPS6KB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4190775-A1 CRYSTAL FORM OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND PREPARATION METHOD THEREFOR Transthera Sciences (Nanjing), Inc. (CN) 2023-06-07 EP disclosed
EP-3395814-B1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORP (US) 2022-04-06 EP disclosed
US-20210347756-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION 2021-11-11 US disclosed
EP-2872491-B1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORP (US) 2021-05-05 EP disclosed
US-10875837-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2020-12-29 US disclosed
EP-3508482-B1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF NANJING TRANSTHERA BIOSCIENCES CO LTD (CN) 2020-12-16 EP disclosed
US-10744139-B2 Inhibitors of fibroblast growth factor receptor and use thereof NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) 2020-08-18 US disclosed
US-20200108070-A2 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) 2020-04-09 US disclosed
US-20200109127-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2020-04-09 US disclosed
US-20190209564-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF NANJING TRANSTHERA BIOSCIENCES CO LTD (CN) 2019-07-11 US disclosed
EP-3508482-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF Nanjing Transthera Biosciences Co. Ltd. (CN) 2019-07-10 EP disclosed
US-10221154-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2019-03-05 US disclosed
WO-2018040885-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF 南京药捷安康生物科技有限公司 2018-03-08 WO disclosed
US-20170174652-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION 2017-06-22 US disclosed
US-20150119405-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2015-04-30 US disclosed
WO-2015061572-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2015-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10744139-B2 Inhibitors of fibroblast growth factor receptor and use thereof FGFR1, FGFR2, FGFR3 FGFR4 6/4885FGFR1 1/4885FGFR2 2/4885
US-20200109127-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR4, FGFR1, FGFR2 FGFR4 1/4885FGFR1 2/4885FGFR2 3/4885
US-20210347756-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR4, FGFR1, FGFR2 FGFR4 1/4885FGFR1 2/4885FGFR2 3/4885
US-20170174652-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR4, FGFR1, FGFR2 FGFR4 1/4885FGFR1 2/4885FGFR2 3/4885
US-10875837-B2 Inhibitors of the fibroblast growth factor receptor FGFR4, FGFR1, FGFR2 FGFR4 1/4885FGFR1 2/4885FGFR2 3/4885
US-20200108070-A2 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF FGFR1, FGFR2, FGFR3 FGFR4 6/4885FGFR1 1/4885FGFR2 2/4885
US-20190209564-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF FGFR1, FGFR2, FGFR3 FGFR4 6/4885FGFR1 1/4885FGFR2 2/4885
US-20150119405-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR4, FGFR1, FGFR2 FGFR4 1/4885FGFR1 2/4885FGFR2 3/4885
US-10221154-B2 Inhibitors of the fibroblast growth factor receptor FGFR4, FGFR1, FGFR2 FGFR4 1/4885FGFR1 2/4885FGFR2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.